AstraZeneca (AZN.L, AZN) has reported promising top-line results from an interim analysis of the Phase III AMPLIFY trial. The study revealed that a fixed-duration regimen of Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) compared to the standard chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia (CLL).
Regarding the secondary endpoint of overall survival (OS), data indicated a favorable trend for Calquence combined with venetoclax, with or without obinutuzumab, against standard-of-care chemoimmunotherapy. However, the OS data were immature at the time of this analysis, and the study will continue to monitor overall survival as a key secondary endpoint.
Chronic lymphocytic leukemia, characterized by the abnormal production of white blood cells, is the most common type of leukemia in adults globally, with cases expected to rise.
